Company attributes
Industry
Location
B2X
Founder
Pitchbook URL
Parent Organization
Number of Employees (Ranges)
11 – 50
Email Address
claris@revealbio.com
Phone Number
+185827436630
Number of Employees
25
Full Address
6760 Top Gun St, Suite 110, San Diego, CA 921210
Investors
DUNS Number
078531542
Founded Date
2012
0Latest Funding Type
Motto/Tagline
Data Powered Pathology
Country
Other attributes
Company Operating Status
Active
Reveal Biosciences was founded by Claire Weston & Casey Laris in 2012 to develop pathology systems that are driven by artificial intelligence to analyze and collect data on whole slide samples.
Reveal Biosciences was created initially for cancer pathology; however, the technology and machinery developed is capable of running diagnostics on many diseases and is capable of assisting in pre-clinical research, clinical trials, and individual patient diagnosis and care.
COVID-19 Response:
Comprehensive services include ISH staining, whole slide imaging, and quantitative analysis.
New SARS-CoV-2-specific mRNA probes:
- V-nCoV2019-S. This probe targets the S gene encoding the spike protein. This probe has been designed to be specific for SARS-CoV-2 and will not detect other coronaviruses.
- V-nCoV2019-S-sense. This “sense” probe targets the antisense strand of the S gene, which can be used to visualize viral replication in individual cells.
- Hs-ACE2. ACE2 is the cellular receptor for SARS-CoV-2. This probe will provide highly sensitive detection of ACE2 expression in cells and tissue sections, information critical to understanding the tropism and pathogenesis of this novel virus.
- Hs-TMPRSS2. TMPRSS2 is a cellular serine protease and primes the spike protein (S) for cellular entry.
Timeline
No Timeline data yet.
